These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28544032)

  • 61. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
    Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
    Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Diminished ovarian reserve in women with transfusion-dependent beta-thalassemia major: Is iron gonadotoxic?
    Uysal A; Alkan G; Kurtoğlu A; Erol O; Kurtoğlu E
    Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():69-73. PubMed ID: 28732253
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Iron chelation with oral deferiprone in patients with thalassemia.
    Grady RW; Giardina PJ
    N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
    [No Abstract]   [Full Text] [Related]  

  • 66. Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
    Zachariah M; Tony S; Bashir W; Al Rawas A; Wali Y; Pathare A
    Pediatr Hematol Oncol; 2013 Mar; 30(2):104-12. PubMed ID: 23363369
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting.
    Del Vecchio GC; Crollo E; Schettini F; Schettini F; Fischer R; De Mattia D
    Acta Haematol; 2000; 104(2-3):99-102. PubMed ID: 11154982
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New concept in natural history and management of diabetes mellitus in thalassemia major.
    Chatterjee R; Bajoria R
    Hemoglobin; 2009; 33 Suppl 1():S127-30. PubMed ID: 20001615
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia.
    Kurtoglu AU; Kurtoglu E; Temizkan AK
    Endokrynol Pol; 2012; 63(4):260-3. PubMed ID: 22933160
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Correlation of Pancreatic Iron Overload Measured by T2*-Weighted Magnetic Resonance Imaging in Diabetic Patients with β-Thalassemia Major.
    Kosaryan M; Rahimi M; Darvishi-Khezri H; Gholizadeh N; Akbarzadeh R; Aliasgharian A
    Hemoglobin; 2017 May; 41(3):151-156. PubMed ID: 28762844
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study.
    Pepe A; Meloni A; Rossi G; Caruso V; Cuccia L; Spasiano A; Gerardi C; Zuccarelli A; D'Ascola DG; Grimaldi S; Santodirocco M; Campisi S; Lai ME; Piraino B; Chiodi E; Ascioti C; Gulino L; Positano V; Lombardi M; Gamberini MR
    Br J Haematol; 2013 Nov; 163(4):520-7. PubMed ID: 24111905
    [TBL] [Abstract][Full Text] [Related]  

  • 76. How early can myocardial iron overload occur in beta thalassemia major?
    Yang G; Liu R; Peng P; Long L; Zhang X; Yang W; Tan S; Pan H; Long X; He T; Anderson L; Lai Y
    PLoS One; 2014; 9(1):e85379. PubMed ID: 24465548
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pancreatic iron and glucose dysregulation in thalassemia major.
    Noetzli LJ; Mittelman SD; Watanabe RM; Coates TD; Wood JC
    Am J Hematol; 2012 Feb; 87(2):155-60. PubMed ID: 22120775
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.
    Musallam KM; Taher AT
    Haematologica; 2011 Feb; 96(2):e5-6; author reply e7-8. PubMed ID: 21282714
    [No Abstract]   [Full Text] [Related]  

  • 80. Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
    Dadheech S; Rao AV; Shaheen U; Hussien MD; Jain S; Jyothy A; Munshi A
    Gene; 2013 Dec; 531(2):301-5. PubMed ID: 24036429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.